Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia.
The last earnings update was 35 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Mainstay Medical International. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Mainstay Medical International's
is considered below, and whether this is a fair price.
Price based on past earnings
Mainstay Medical International's earnings available for a low price, and how does
this compare to other companies in the same industry?
Mainstay Medical International's earnings are expected to grow significantly at over 20% yearly.
Mainstay Medical International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
All data from Mainstay Medical International Company Filings, last reported 4 months ago, and in
Trailing twelve months (TTM)
annual period rather than quarterly.
ISE:MSTY1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions)
Net Income *
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
It is difficult to establish if Mainstay Medical International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
It is difficult to establish if Mainstay Medical International has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
It is difficult to establish if Mainstay Medical International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Mainstay Medical International's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Mainstay Medical International
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Mainstay Medical International's finances.
The net worth of a company is the difference between its assets and liabilities.
Mainstay Medical International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Mainstay Medical International's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Mainstay Medical International's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.6x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jason Marshall Hannon, Esq., serves as Director of Kuros Biosciences AG since June 14, 2018. He has been the Chief Executive Officer of Mainstay Medical International plc since October 9, 2017. Mr. Hannon served as Consultant of NuVasive, Inc. since September 1, 2017 until December 31, 2017 and served as its President and Chief Operating Officer from September 11, 2016 to August 1, 2017. Mr. Hannon served as an Executive Vice President of International at NuVasive, Inc. since July 16, 2015 until September 11, 2016 and served as its General Counsel from January 2007 to December 1, 2015. He served as an Executive Vice President of Corporate Development at NuVasive, Inc. from January 1, 2010 to July 2015 and served as its Secretary from January 2007 to July 2015. Mr. Hannon served as Executive Vice President of NuVasive, Inc. since January 1, 2010 and served as its Senior Vice President from January 2007 to January 2009. He served as Senior Vice President of Corporate Development of NuVasive, Inc. from January 2009 to January 1, 2010. He served as Vice President of Legal Affairs at Nuvasive, Inc. from June 14, 2005 to January 2009 and was a Consultant since August 1, 2017 until September 1, 2017. Mr. Hannon was employed at Heller Ehrman LLP. Mr. Hannon served as a Law Clerk to the Honorable Jerome Farris of the U.S. Court of Appeals for the Ninth Circuit. Mr. Hannon practiced corporate and transactional law at the law firms of Brobeck Phleger & Harrison LLP. Mr. Hannon has broad medical device experience has spanned areas like critical commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management and the building of a high-performance culture. He has been a Director of Mainstay Medical International plc since October 9, 2017. He served as a Director of Nemaris, Inc. Mr. Hannon holds a B.A. degree from the University of California at Berkeley and a J.D. from Stanford Law School.
Insufficient data for Jason to compare compensation growth.
Jason's remuneration is higher than average for companies of similar size in Ireland.
Management Team Tenure
Average tenure and age of the
Mainstay Medical International
management team in years:
The average tenure for the Mainstay Medical International management team is less than 2 years, this suggests a new team.
CEO & Director
CFO & Company Secretary
Chief Operating Officer
Vice President of Marketing
VP & MD of Germany
Board of Directors Tenure
Average tenure and age of the
Mainstay Medical International
board of directors in years:
The tenure for the Mainstay Medical International board of directors is about average.
Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia. It develops ReActiv8, an implantable restorative neurostimulation system to treat people with disabling chronic low back pain. The company was formerly known as Mainstay Medical plc and changed its name to Mainstay Medical International plc in March 2014. Mainstay Medical International plc was founded in 2008 and is headquartered in Dublin, Ireland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.